<DOC>
	<DOCNO>NCT01857323</DOCNO>
	<brief_summary>This prospective , open-label , multicenter Phase 3 study evaluate performance Albuterol Spiromax dose counter patient diagnosis asthma and/or COPD . The purpose study evaluate functionality , reliability , accuracy Albuterol Spiromax inhaler integrate dose counter clinical setting .</brief_summary>
	<brief_title>Open-Label Assessment Albuterol Spiromax® Dry Powder Inhaler ( DPI )</brief_title>
	<detailed_description>The study consist screening/run-in period , meeting study criterion , patient enter run-in period last 7 14 ±2 day , diary medication compliance , well inhaler technique , assess . The run-in period commence day follow completion screen procedure continue include day prior first treatment visit ( TV1 ) minimum 7 full day diary data collect prior TV1 . The purpose run-in period assess compliance BID dose regimen completion diary entry minimum period 7 day . Patients demonstrate adequate inhaler technique least 90 % compliant dosing completion diary last 7 consecutive day run-in qualify enrollment open-label study . The study treatment period comprise 6 treatment visit ( TV1-TV6 ) enrol patient except 5-week treatment cohort 5 treatment visit ( TV1-TV5 ) . Patients may continue take current asthma COPD medication throughout Treatment Period . The patient return clinic Days 8 ( ±1 ) , 15 ( ±1 ) , 22 ( ±1 ) , 36 ( ±1 ) , Day 50 ( -2 ) approximately 200 dos deliver , early withdrawal . The patient deem complete study least 90 % recommended dos contain Albuterol Spiromax dose-counter use . A representative sample ( approximately 15 % ) patient participate trial approximately 5 week Day 36 ( ±1 ) final study visit .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>1 . Written inform consent/assent sign dated patient and/or parent/legal guardian conducting study related procedure 2 . Male female ( non pregnant/non lactate ) patient 4 year age old time screen visit ( SV ) able understand English 3 . Females childbearing potential ( judged investigator ) currently use continue use medically reliable method contraception entire study duration ( e.g . oral , injectable , transcutaneous implantable contraceptive intrauterine device doublebarrier protection ) . Females sexually active must agree use medically reliable method contraception become active course study . Women childbearing potential , less 1 year postmenopausal , require negative urine pregnancy test SV . Female patient consider nonchildbearing potential require urine pregnancy test least one follow apply : a. menarche ; b. one year postmenopausal ; c. hysterectomy , bilateral oophorectomy , salpingectomy , tubal ligation ; d. congenital sterility 4 . General good health , define free concomitant condition treatment could interfere study conduct , influence interpretation study observations/results , put patient increase risk study 5 . Has physician diagnosis asthma COPD symptom bronchoconstriction require use shortacting β2agonists 6 . Current Therapy : The patient 's current asthma/COPD controller treatment regimen remain stable least four week prior SV 7 . Capable understanding requirement , risk , benefit study participation , , judge investigator , capable give informed consent/assent compliant study requirement ( visit , record keep , etc ) 8 . Able demonstrate satisfactory Spiromax inhaler use technique . 1 . History lifethreatening asthma COPD define protocol asthma COPD episode require intubation and/or associate hypercapnea , respiratory arrest , hypoxic seizure 2 . Culturedocumented suspected bacterial viral infection upper low respiratory tract , sinus , middle ear resolve within 2 week SV ; occur SV TV1 3 . Is treated longacting β2agonist alone 4 . Any asthma exacerbation require oral corticosteroid within 2 month SV COPD exacerbation require oral corticosteroid within 1 month SV . A patient must hospitalize asthma COPD within 4 month prior SV . 5 . Historical current evidence clinically significant disease include , limited : cardiovascular ( e.g. , congestive heart failure , know aortic aneurysm , clinically significant cardiac arrhythmia coronary heart disease , cerebrovascular accident ) , hepatic , renal , hematological , neuropsychological , endocrine ( e.g. , uncontrolled diabetes mellitus , uncontrolled thyroid disorder , Addison 's disease , Cushing 's syndrome ) , and/or gastrointestinal ( e.g. , poorlycontrolled peptic ulcer gastroesophageal reflux disease [ GERD ] ) . Significant defined disease , opinion investigator , would put safety patient risk participation , could affect endpoint analysis disease/condition exacerbate study . 6 . Uncontrolled hypertension ( systolic blood pressure [ BP ] ≥160 mmHg diastolic BP &gt; 100 mmHg ) 7 . History adverse reaction , include immediate delay hypersensitivity β2agonist , sympathomimetic drug , component Albuterol Spiromax DPI rescue ProAir Hydrofluoroalkane ( HFA ) Metereddose inhaler ( MDI ) formulation . 8 . Other exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>asthma</keyword>
	<keyword>chronic obstructive pulmonary disease</keyword>
	<keyword>COPD</keyword>
	<keyword>Albuterol Spiromax®</keyword>
</DOC>